Pharmaceutical Outsourcing covers news of importance to the contract services segment of the pharmaceutical industry.
Collected from the most trusted on-line resources, these news stories are chosen and published here based on their relevance to the pharmaceutical industry.
Topics of interest typically include: mergers and acquisitions, service additions, new capabilities, personnel changes, news from the FDA and other international regulatory and standard-setting agencies, and new outsourcing contracts and deals.
If you are looking to stay up-to-date with the news in your industry, this resource is vital for your industry knowledge.
Catalent announced financial results for the fourth quarter and fiscal year 2018, which ended June 30, 2018.
read more
Monday, February 05, 2018
Catalent announced financial results for the second quarter of fiscal 2018, which ended December 31, 2017.
read more
Tuesday, February 07, 2017
Catalent, a global provider of advanced delivery technologies and development solutions for drugs, biologics and consumer health products, has announced financial results for the second quarter of fiscal year 2017, which ended December 31, 2016.
read more
Catalent announced financial results for the third quarter of fiscal year 2019, which ended March 31, 2019.
read more
Catalent a global provider of advanced delivery technologies and development solutions for drugs, biologics and consumer health products, has announced financial results for the third quarter of fiscal year 2016, which ended March 31, 2016.
read more
Catalent announced Catalent Biologics will provide vial filling and packaging capacity to AstraZeneca PLC at Catalent’s manufacturing facility in Anagni, Italy.
read more
Catalent announced a collaboration with Ennaid Therapeutics to develop an oral, antiviral treatment targeted at COVID-19.
read more
Tuesday, September 05, 2017
SGS has consolidating its consultancy portfolio into a single, comprehensive offering.
read more
Friday, December 04, 2020
Catalent has entered into a commercial supply agreement with Blueprint Medicines following FDA approval of GAVRETO.
read more
Wednesday, February 10, 2021
Catalent hadssigned an agreement with Trizell GmbH, to support the manufacturing of Trizell’s Phase 1 cell therapy for the treatment of micro- and macroangiopathies.
read more
Catalent welcomed the news from Nocion Therapeutics that its first patient has been dosed with NOC-100, an inhaled formula of its NTX-1175 small molecule candidate.
read more
Monday, November 02, 2020
Catalent has signed an agreement with Bone Therapeutics to acquire its cell therapy manufacturing subsidiary, Skeletal Cell Therapy Support.
read more
Tuesday, September 19, 2017
Catalent has reached an agreement to acquire Bloomington, Indiana-based Cook Pharmica, an integrated provider of drug substance and drug product manufacturing and related services.
read more
Friday, February 26, 2021
Catalent and Delphi Genetics have entered into a final and definitive agreement whereby Catalent will acquire 100% of the shares of Delphi Genetics.
read more
Wednesday, January 13, 2021
Catalent has entered into a definitive agreement to acquire the manufacturing and packaging operations of Acorda Therapeutics.
read more